CClinicalTrials.gg
Status unknownNCT02972151Updated Nov 23, 2016

Clinical Research of TCM on Pelvic Inflammatory Disease Sequelae

A Phase 2 interventional study of Comprehensive treatment of TCM and Expectant treatment in Pelvic Inflammatory Disease, sponsored by Shanghai University of Traditional Chinese Medicine. Status unknown at 1 site in China. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2016-11-23.

Sponsored by Shanghai University of Traditional Chinese Medicine · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2016), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

The trial attempts to optimize, standardize and simplify the characteristic diagnosis and treatment program of the dominant diseases in our hospital-the sequelae of pelvic inflammatory disease, so as to make it suitable for clinical diagnosis and treatment in primary hospital.

Read the detailed description

Sequelae of pelvic inflammatory disease (SPID) is a common cause of chronic pelvic pain, ectopic pregnancy and infertility, which seriously affects the physical and mental health of the patients, quality of life and family happiness. Western medicine for pelvic inflammatory disease sequelae is still lack of effective treatment methods, traditional Chinese medicine treatment of this disease has a unique advantage, with broad prospects for development..Standardized diagnosis and treatment scheme of this project on the one hand, improve and optimize the sequelae of pelvic inflammatory disease, including according to the dialectical treatment of herbal medicine combined with TCM (traditional Chinese medicine enema, external application of Chinese medicine intervention treatment); on the other hand, to observe the clinical curative effect and adverse reaction of traditional Chinese medicine comprehensive treatment.

02

Conditions studied

  • Pelvic Inflammatory Disease
03

In context

Pelvic Inflammatory Disease

37 studies on the registry are indexed under Pelvic Inflammatory Disease; 5 are open to participants now.

This study's planned enrollment of 175 is close to the median of 163 across 30 interventional studies indexed under Pelvic Inflammatory Disease.

Browse Pelvic Inflammatory Disease studies →

Lead sponsor

Shanghai University of Traditional Chinese Medicine is the lead sponsor of 99 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients with diagnostic criteria for the sequelae of pelvic inflammatory disease in Western medicine;
  2. Patients conforming to the criteria of TCM syndrome differentiation;
  3. Age 18--60 years old, married or sexual life;
  4. In this study, the voluntary participation, and signed informed consent;

Exclusion criteria

Exclusion Criteria:

  1. Patients who do not meet the diagnostic criteria of Western medicine and traditional Chinese medicine dialectical typing standard;
  2. Persons with acute pelvic inflammatory disease;
  3. Related symptoms caused by diseasesGynecological tumor,specific vaginitis, acute cervicitis, pelvic congestion syndrome, endometriosis, adenomyosis, pelvic tuberculosis etc.
  4. Pregnant and lactating women;
  5. With severe primary disease, such as liver, kidney, heart, brain and hematopoietic system;
  6. Allergic to a variety of drugs or known to be allergic to the composition of the use of traditional Chinese Medicine;
  7. Patients taking part in other clinical trials;
  8. Suspect or do have a history of alcohol, drug abuse or according to the judgment of the researcher,other lesions or circumstances that have reduced the likelihood of entering a group or the complexity of entering a group,such as frequent changes in the working environment, the living environment is not stable,etc.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
175 participants (estimated)

Study arms

  • Experimental
    Comprehensive treatment of TCM

    The intervention is Comprehensive treatment of TCM,which including Oral medicine ,tradition chinese medicine enema, external treatment.

    Drug: Comprehensive treatment of TCM

  • Active comparator
    Expectant therapy

    Expectant treatment group patients were not treated during the observation period. (3 months after the start of the trial and 1 months after the end of the trial.)

    Other: Expectant treatment

Interventions

  • DrugComprehensive treatment of TCM

    Subjects were treated with comprehensive treatment of TCM including Oral medicine: 1 dose daily by our hospital pharmacy medicine room Decoction decoction, each agent 200ml, and the 2 ton service. 10 days for a course of treatment, continuous treatment of 3 courses; retention enema with traditional Chinese medicine oral drugs according to different types of concentrated decoction enema, each dose of medicine decocting 2 times, 2 days of external application of Chinese medicine: Chinese medicine enema; break into powder, into the bag, steam for 45 minutes, and so the temperature dropped to appropriate, will be installed a Chinese medicine bag used on patients with lower abdomen for 20 minutes. Above method, a course of treatment for 10 days, continuous treatment of 3 courses.

    Also known as: Oral medicine and TCM enema, external treatment

  • OtherExpectant treatment

    Expectant treatment group patients were not treated during the observation period.(3 months after the start of the trial and 1 months after the end of the trial.)From the point of view of medical ethics, the expectant treatment group of patients at the end of the observation period, given the treatment of traditional Chinese medicine treatment group.

    Also known as: Do not give any treatment

06

What researchers measure

Primary outcomes

  1. changes of The Symptom score

    Patients are checked The Symptom score at 3 months after treatment.

    Time frame: 3 months after treatment

Secondary outcomes

  1. changes of The Hamilton Depression Scale (HAMD) (17 items)

    Time frame: 1 months after treatment, 2 months after treatment, 3 months after treatment and 1 months after drug withdrawal.

  2. changes of The Sign score sheet

    Time frame: 1 months after treatment, 2 months after treatment, 3 months after treatment and 1 months after drug withdrawal

07

Study locations

1 site
  • Shanghai Longhua Hosptial
    Shanghai, Shanghai, China
    • lianwei xu, Doctor · Contact · sherryxlw@hotmail.com · 64385700-3912
    • lianwei xu, Doctor · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02972151
Lead sponsor
Shanghai University of Traditional Chinese Medicine
Responsible party
Sponsor
First posted
Nov 23, 2016
Start date
Nov 2016
Primary completion
Dec 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Nov 23, 2016

Study contacts

lianwei xu, Doctor
Contact
sherryxlw@hotmail.com
64385700-3912
qianjue tang
Contact
64385700-3912
lianwei xu, Doctor
principal investigator · Shanghai Longhua Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion